These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7559201)

  • 1. Combined therapy with co-amoxiclav and erythromycin against intracellular Legionella pneumophila in cell culture and in an experimental respiratory infection in neutropenic rats.
    Smith GM; Abbott KH; Beale AS
    J Antimicrob Chemother; 1995 Jun; 35(6):889-93. PubMed ID: 7559201
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of amoxycillin-clavulanic acid against Legionella pneumophila in vitro and in an experimental respiratory infection model.
    Smith GM; Sutherland R
    J Hosp Infect; 1992 Nov; 22 Suppl A():61-7. PubMed ID: 1362751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal effects of co-amoxiclav (amoxycillin clavulanic acid) against a Legionella pneumophila pneumonia in the immunocompromised weanling rat.
    Smith GM; Abbott KH; Sutherland R
    J Antimicrob Chemother; 1992 Oct; 30(4):525-34. PubMed ID: 1490922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal effects of amoxycillin/clavulanic acid against a Legionella pneumophila pneumonia in the weanling rat.
    Smith GM; Abbott KH; Wilkinson MJ; Beale AS; Sutherland R
    J Antimicrob Chemother; 1991 Jan; 27(1):127-36. PubMed ID: 2050589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bactericidal effects of amoxycillin/clavulanic acid (augmentin) against Legionella pneumophila in vitro and in tissue culture studies.
    Stokes DH; Wilkinson MJ; Slocombe B; Sutherland R
    J Chemother; 1989 Jul; 1(4 Suppl):84-5. PubMed ID: 16312315
    [No Abstract]   [Full Text] [Related]  

  • 6. Bactericidal effects of ticarcillin-clavulanic acid against Legionella pneumophila pneumonia in immunocompromised weanling rats.
    Smith GM; Abbott KH; Wilkinson MJ; Beale AS; Sutherland R
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1423-9. PubMed ID: 1929303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.
    Edelstein PH; Edelstein MA
    Antimicrob Agents Chemother; 1994 Feb; 38(2):200-4. PubMed ID: 8192443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The activity of antibiotics against Legionella pneumophila: in vitro and in vivo studies.
    Mizen L
    J Antimicrob Chemother; 2001 Mar; 47(3):359-60. PubMed ID: 11222573
    [No Abstract]   [Full Text] [Related]  

  • 9. Fatal Legionella pneumophila pneumonia: treatment failure despite early sequential oral-parenteral amoxicillin-clavulanic acid therapy.
    Hohl P; Buser U; Frei R
    Infection; 1992; 20(2):99-100. PubMed ID: 1582691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo activities of sparfloxacin in Legionella infections.
    Saito A; Gaja M
    Drugs; 1995; 49 Suppl 2():250-2. PubMed ID: 8549320
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparative study on the efficacy of the new quinolone alatrofloxacin in the treatment of experimental legionellosis in guinea pigs.
    García-de-Lomas J; Millás E; Lázaro MA; Bermejo M; Gimeno C; Navarro D; Sánchez S
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):420-3. PubMed ID: 9758285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of legionnaire's disease due to Legionella pneumophila serogroup 6].
    Takamori M; Nakano K; Ubukata H; Suzuki S; Funaki N; Oyama K; Shimada K
    Nihon Naika Gakkai Zasshi; 1998 Jun; 87(6):1127-9. PubMed ID: 9702025
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro activity of macrolides against intracellular Legionella pneumophila.
    Segreti J; Meyer P; Kapell K
    Diagn Microbiol Infect Dis; 1996 Jul; 25(3):123-6. PubMed ID: 8902407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pericarditis associated with Legionnaires' disease in a bone marrow transplant recipient.
    Scerpella EG; Whimbey EE; Champlin RE; Bodey GP
    Clin Infect Dis; 1994 Dec; 19(6):1168-70. PubMed ID: 7888562
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei.
    Dance DA; Wuthiekanun V; Chaowagul W; Suputtamongkol Y; White NJ
    J Antimicrob Chemother; 1991 Aug; 28(2):321-4. PubMed ID: 1723404
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Legionella pneumophila lung abscess with clindamycin.
    Buggy BP; Saravolatz LD
    Clin Infect Dis; 1995 May; 20(5):1158-62. PubMed ID: 7619992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legionella pneumonia: the spectrum continues to expand.
    Brown RB
    Chest; 2004 Jun; 125(6):1979-80. PubMed ID: 15189909
    [No Abstract]   [Full Text] [Related]  

  • 18. BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs.
    Edelstein PH; Shinzato T; Edelstein MA
    J Antimicrob Chemother; 2001 Nov; 48(5):667-75. PubMed ID: 11679556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Choice of antimicrobial therapy for Legionnella infection].
    de Vries PA; van der Werf TS; Manson WL; Zijlstra JG
    Ned Tijdschr Geneeskd; 2005 Feb; 149(9):452-7. PubMed ID: 15771338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new macrolide, TE-031 (A-56268), in treatment of experimental Legionnaires' disease.
    Kohno S; Koga H; Yamaguchi K; Masaki M; Inoue Y; Dotsu Y; Masuyama Y; Hayashi T; Hirota M; Saito A
    J Antimicrob Chemother; 1989 Sep; 24(3):397-405. PubMed ID: 2530201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.